Boehringer Ingelheim and Boryung Pharmaceuticals have concluded its co-promotion deal for Boehringer Ingelheim’s non-vitamin K antagonist oral anticoagulant (NOAC) therapy ‘Pradaxa (dabigatran).’

Boehringer Ingelheim plans to directly sell Pradaxa starting this year.

According to industry sources on the 21st, Boehringer Ingelheim and Boryung Pharmaceuticals concluded their co-promotion deal for Pradaxa at the end of last year. Rather than find a new partner company to sell its product, Boehringer Ingelheim decided to sell Pradaxa directly.

An official from Boehringer Ingelheim said, “The two companies agreed to terminate the copromotion deal at the end of last year. Th